Novo Nordisk is a global healthcare company headquartered in Denmark, with a prominent focus on diabetes care. Founded in 1923, it has grown into a leader in the pharmaceutical industry, also providing treatments for other serious chronic conditions such as hemophilia, growth hormone-related disorders, and obesity.

The company is renowned for its innovations in the field of insulin and diabetes care technology, including insulin pens and newer forms of injectable and oral therapies. Novo Nordisk is committed to a patient-centered approach and actively engages in sustainability efforts, particularly in reducing its environmental impact. Additionally, Novo Nordisk plays a significant role in global health initiatives, aiming to improve access to diabetes care in under-resourced areas around the world.